Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095337 | 0.88 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL5095329 | 0.88 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL6630868 | 0.88 | GSK3B (0.43) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL6628760 | 0.85 | GSK3B (0.41) | GSK3BCYP2D6CYP1A2 | |
| Oxalic Acid SCHEMBL5098928 | 0.85 | GSK3B (0.39) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL5108456 | 0.82 | DRD2 (0.43) | GSK3BCYP2D6CYP1A2DRD2 | |
| SCHEMBL3563586 | 0.81 | GSK3B (0.46) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL5099053 | 0.80 | GSK3B (0.44) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL5102710 | 0.78 | GSK3B (0.44) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3573851 | 0.77 | GSK3B (0.52) | GSK3BCYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480983-B1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYDIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | claimed |
| EP-1348708-A1 | Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-10-01 | — | — | EP | claimed |
| EP-1480983-B1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYDIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | disclosed |
| EP-1480983-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYDIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | Sanofi-Aventis (FR) | 2004-12-01 | — | — | EP | disclosed |
| EP-1451164-A2 | AMIDE DERIVATIVES HAVING IMPROVED SOLUBILITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1348708-A1 | Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003072579-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003006440-A2 | AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |